GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study

Completed · Phase 4

Conditions studied: Peripheral Vascular Diseases

In brief

To evaluate the performance of the GORE VIABAHN® Endoprosthesis compared to a bare nitinol stent for the treatment of superficial femoral artery (SFA) occlusive disease in long lesions.

Key facts

Study ID

NCT00228384

Run by

W.L.Gore & Associates

People needed

148

Starts

2005-09-01

Expected to finish

2011-01-01

Last updated by the study team

2012-06-04

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Lifestyle-limiting claudication or rest pain.
• Subject (or their legal guardian) has read, understood and provided written informed consent.
• At least 21 years of age.
• Quality of life questionnaires completed.
• Noninvasive lower extremity arterial studies within 45-days prior to study procedure.
• If applicable, staged ipsilateral vascular procedure ≥ 14-days prior to study procedure.
• If applicable, vascular treatment on non-study leg for bilateral claudication ≥ 14-days prior to study procedure.
• Male, infertile female, or female of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test.
• Projected life expectancy of greater than three years.
• The ability to comply with protocol.
• Angiographic and Lesion Requirements meets protocol criteria.

You may not qualify if…

• Untreated flow-limiting aortoiliac occlusive disease.
• Any previous stenting or surgery in the target vessel.
• Subjects with arterial lesions requiring treatment with device diameters other than 6, 7, or 8 mm.
• Severe ipsilateral common femoral/profunda disease requiring surgical intervention.
• Femoral or popliteal aneurysm.
• Non-atherosclerotic disease resulting in occlusion.
• Tibial artery disease requiring treatment.
• Prior ipsilateral femoral artery bypass.
• Severe medical comorbidities.
• Popliteal artery vascular access at any time during procedure.
• Antegrade and retrograde vascular access on the same common femoral artery at the time of the SFA intervention.
• Serum creatinine > 2.5 mg/dL within 45 days prior to study procedure.
• Major distal amputation.
• Septicemia.
• Any previously known coagulation disorder.
• Morbid obesity or operative scarring that precludes percutaneous approach (physician's discretion).
• Contraindication to anticoagulation or antiplatelet therapy.
• Known allergies to stent/stent-graft components.
• History of prior life-threatening reaction to contrast agent.
• Currently participating in another clinical research trial.
• Current peritoneal or hemodialysis.

Where it is running

• Mayo Clinic Phoenix — Phoenix, Arizona, United States
• Arkansas Heart — Little Rock, Arkansas, United States
• Holy Cross Hospital — Fort Lauderdale, Florida, United States
• Vascular Surgical Associate — Austell, Georgia, United States
• Midwest Heart Foundation — Lombard, Illinois, United States
• Midwest Institute for Minimally Invasive Therapy — Melrose Park, Illinois, United States
• St Francis Medical Center — Peoria, Illinois, United States
• St. Johns Hospital/Prairie Education Research — Springfield, Illinois, United States
• Ochsner Clinic — New Orleans, Louisiana, United States
• Washington University — St Louis, Missouri, United States
• The Cleveland Clinic Foundation — Cleveland, Ohio, United States
• Midwest Cardiology Research Foundation — Columbus, Ohio, United States
• Heritage Valley Health Systems — Beaver, Pennsylvania, United States
• Allegheney General Hospital — Pittsburgh, Pennsylvania, United States
• St Luke's Medical Center — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.